Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. NASDAQ:SPRO, a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for immune-mediated diseases, today announced financial results for the third quarter ended September 30, 2026, and pro…